Comparison of clinical characteristics, microvascular complications and inflammatory markers in type 2 diabetic patients under insulin versus metformin treatment: A cross-sectional study at Karbala Diabetic Center, Iraq
Open Access
- 1 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (44) , e40330
Abstract
Type 2 diabetes mellitus (T2DM) is a major global health issue associated with chronic inflammation, which contributes to both disease progression and its complications, including cardiovascular and microvascular disorders. Key inflammatory markers such as tumor necrosis factor-alpha, interleukin-6 (IL-6), E-selectin, and P-selectin are elevated in T2DM patients and are implicated in the development of these complications. Understanding how treatments such as insulin and metformin affect these markers is crucial for improving therapeutic strategies in T2DM. This study investigated the effects of insulin and metformin on these inflammatory markers in T2DM patients. This was a cross-sectional study involving patients with diabetes on insulin (group A), metformin only (group B), and healthy controls (group C). Participants were enrolled from the Diabetic Center in Karbala, Iraq and underwent clinical assessments including ophthalmologic examinations. Fasting blood glucose, HbA1c and lipids levels were assessed. The levels of inflammatory markers (IL-6 and TNF-α), and adhesion molecules (sE-selectin and sP-selectin) were measured using Enzyme-Linked Immunosorbent Assay (ELISA). The study included 522 patients with diabetes: 356 receiving insulin (group A), 70 receiving metformin (group B) and 96 healthy controls (group C). T2DM patients treated with insulin exhibited significantly more microvascular complications than those treated with metformin. Higher rates of retinopathy (64.3% vs 11.4%) and neuropathy (69.9% vs 11.4%) were observed in the insulin group, whereas the incidence of nephropathy did not differ significantly (14.6% vs 11.4%). Inflammatory markers were lower in the insulin group: TNF-α levels were 3-fold lower and IL-6 levels were 8-fold lower. Conversely, sE-selectin levels were 1.5-fold higher in the insulin group, and sP-selectin levels were 1.4-fold higher in the metformin group. This study highlights distinct differences in inflammatory markers and systemic complications between T2DM patients treated with insulin and those treated with metformin alone. Further research is needed to explore the mechanisms underlying these observations and optimize treatment strategies for T2DM patients.Keywords
This publication has 37 references indexed in Scilit:
- The potential impact and diagnostic value of inflammatory markers on diabetic foot progression in type II diabetes mellitus: A case–control studyMedicina Clinica, 2024
- Early effects of insulin therapy on cholesterol synthesis and absorption markers in patients with type 2 diabetesClinical Nutrition Open Science, 2023
- Inflammatory markers and control of type 2 diabetes mellitusDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019
- Plasma E-selectin levels can play a role in the development of diabetic retinopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- Impact of Insulin Treatment in Diabetic Macular Edema Therapy in Type 2 DiabetesCanadian Journal of Diabetes, 2015
- Independent anti‐inflammatory effect of insulin in newly diagnosed type 2 diabetesDiabetes/Metabolism Research and Reviews, 2009
- Inflammatory cytokines in insulin-treated patients with type 2 diabetesNutrition, Metabolism and Cardiovascular Diseases, 2008
- Proinflammatory Effects of Glucose and Anti-Inflammatory Effect of Insulin: Relevance to Cardiovascular DiseaseThe American Journal of Cardiology, 2007
- Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetesDiabetologia, 2002
- The Effect of Glycaemic Control and the Introduction of Insulin Therapy on Retinopathy in Non-insulin-dependent Diabetes MellitusDiabetic Medicine, 1997